Congratulations to our client Ascendis Pharma for appointing Chad Fugere as Vice President, Investor Relations.
Ascendis Pharma is a global biopharmaceutical company focused on applying their innovative TransCon technology platform to make a meaningful difference for patients. Guided by core values of Patients, Science, and Passion, and following an algorithm for product innovation, the company applies TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Publicly traded (ASCENDIS: ASND), current and historical investors have included RA Capital Management, T. Rowe Price, Sofinnova Investments, OrbiMed, Gilde Healthcare, Vivo Capital, Frazier Life Sciences, venBio, HealthQuest Capital, and Royalty Pharma.
C1 Team: Christos Richards & James Reynolds